PROGNOSTIČKI ZNAČAJ INTRATEKALNOG OLIGOKLONALNOG IMUNOGLOBULINA G U MULTIPLOJ SKLEROZI
Ključne reči:
Oligoklonalne trake, Multipla skleroza, Prognoza
Sažetak
Uvod/cilj: Detekcija intratekalnih oligoklonalnih traka imunoglobulina G (OT IgG), osim dijagnostičkog, ima i prediktivni značaj u multiploj sklerozi (MS). Cilj studije je da se odredi prognostički značaj OT IgG, te korelira prisustvo OT IgG sa progresijom onesposobljenosti kod MS bolesnika.
Metode: Studija je kohortna retrospektivno-prospektivna i obuhvatala je 177 MS bolesnika i 271 pacijenata kontrolne grupe, ispitivanih u Centru za MS Neurološke klinike Univerzitetskog kliničkog centra Republike Srpske. Kod svih pacijenata su analizirani: demografski podaci, klinički parametri, EDSS skor (eng.Expanded Disability Status Scale), IEF (izoelektrično fokusiranje) likvora,citobiohemijska analiza likvora, evocirani potencijali (EP) i magnetna rezonanca (MR) glave. Prema EDSS određenom u obje grupe analizirana je povezanost stepena funkcionalne onesposobljenosti sa prisustvom OT u likvoru, te sa karakteristikama citobiohemijskog profila. U analizi rezultata korištene su metode deskriptivne i analitičke statistike, analiza varijanse, hi kvadrat test, Bonferonijev post hoc test, korelacione i regresione analize.
Rezultati: U ispitivanoj kohorti MS bolesnika senzitivnost IEF je bila 96,6%. Postojala je statistički značajna razlika (p=0,004) između pozitivnosti IEF i EDSS. MS bolesnici sa koncentracijom proteina u likvoru >0.40 g/L imaju 2,45 puta veću šansu da uđu u sekundarnu progresiju i 2,51 puta veću šansu da postignu EDSS 4.0.
Zaključak: IEF je veoma senzitivna dijagnostička i prognostička metoda za MS bolesnike, koja ukazuje na benigniji tok MS kod bolesnika bez oligoklonalnih traka u likvoru. MS bolesnici sa intratekalnom sintezom IgG imaju veći stepen funkcionalne onesposobljenosti, izraženo EDSS skorom, u odnosu na one bez intratekalne sinteze.
Reference
1. Awad A, Hemmer B, Hartung HP, Kieseier B, Bennett JL, Stuve O. Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. J Neurol. 2010; 219: 1-7.
2. Autor, 2013.
3. Drulović J. Analiza oligoklonalnog imunoglobulina G u diferencijalnoj dijagnozi neuroloških obolenja. Medicinski fakultet Univerziteta u Beogradu, doktorska disertacija, 1994.
4. Rolas JI, Patricco TS, Cristiana E. Oligoclonal bands in multiple sclerosis patients: worse prognosis. Neurol Res 2012;34(9):889-892.
5. Drulović J, Stojisavljević N, Dujmović. Findings of cerebrospinal fluid in the diagnosis of multiple scleorosis. Srp Arh Celok Lek 1995; 123: 7-8.
6. Dell Avvento S, Sotgio MA, Mance S, Sotgiu G, Sotgiu S. Epidemiology of multiple sclerosids in the pediatric population of Sardinia, Italy. Eur J Pediatr. 2016; 175(1): 19-21.
7. Waldman A, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu m, Banwell B. Multiple sclerosis in children: an update on clinical diagnosis therapeutic strategies, and research. Lancet Neurol. 2014; 13(9): 936-948.
8. Ghasemi N, Razavi S, Nikzad E. Multiple Sclerosis: Pathogenesis, Symptoms, Diagnosis and Cell-Based Therapy. Cell J 2017; 19(1): 1-10.
9. Holloman JP, Ho CC, Hukki A, Huntley JL, Gallicano GI. The development of hematopoietic and mesenchymal stem cell transplantation as an effective treatment for multiple sclerosis. Am J Stem Cells. 2013;2(2):95–107.
10. Gelfand JM. Multiple sclerosis: diagnosis, differential diagnosis, and clinical presentation. Handb Clin Neurol. 2014;122:269–290.
11. Fredrikson S. Clinical usefulness of cerebrospinal fluid evaluation. Intern Mult Scler J. 2010;17:24-27.
12. Dutta R, Trapp BD. Relapsing and progressive forms of multiple sclerosis – insights from pathology. Curr Opin Neurol. 2014; 27(3). 271-278.
13. Miller DH, Chard DT,Cicconelli O.Clinically isolated syndromes. Lancet Neurol 2012;11:157-169.
14. Dujmovic BI, Drulović J, Pekmezovic T. Prirodni tok i prognoza multiple skleroze. U: Drulović J. Multipla skleroza. Medicinski fakultet Univerziteta u Beogradu 2013; 32-46.
15. Lublin FD, Reingold CS, Cohen AJ, Cutter RG, Sorenson PS. Defining the clinical course of multiple sclerosis: he 2013. revisions. Neurology. 2014; 83(3): 278-286.
16. Stangel M, Fredrikson S, Meinl E, Petzold E. The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat Rev Neurol 2013;10:41.
17. Lublin FD. New multiple sclerosis phenotypic classification. Eur Neurol. 2014; 72(1):1-5.
18. Kale N. Optic neuritis as an early sign of multiple sclerosis. Eye Brain. 2016; 8: 195-202.
19. Adam MK, Krespan K, Moster ML, Serott RC. Simultaneous, Bilateral Ophthalmoplegia as the Presenting Sign of Paediatric Multiple Sclerosis: Case Report and Discussion of the Differential Diagnosis. Neuroophtalmology. 2014; 38(4): 230-237.
20. Avasarala JP, Cross AH, Trotter JL. Oligoclonal band number as a marker for prognosis in multiple sclerosis. Arch Neurol 2001;18:2044-2046.
21. Rolas JI, Patricco TS, Cristiana E. Oligoclonal bands in multiple sclerosis patients: worse prognosis. Neurol Res 2012;34(9):889-892.
22. Schneger R, Souza MD, Schindler C, Grize L, Dellas S, Radne EW. Prediction of long-term disability in multiple sclerosis. Mult Scler 2012;18(1):31-38.
23. Swanton JK, Rovira A, Tintore M, Altmann DR, Barkhof F, Filippi M et al. MRI criteria for multiple sclerosis in patient presenting with clinically isolated syndromes:a multicentre retrospective study. Lancet Neurol 2007;6:677-686.
24. Autor, 2011.
25. Aktas O, Wattjes MP, Sangel M, Hartung HP. Diagnosis of multiple sclerosis: revision of the McDonald criteria 2017. Nervenarzt. 2018 Jun 6. doi: 10.1007/s00115-018-0550-0.
26. Drulovic J, Basic-Kes V, Grgic S, Vojinovic S, Dincic E, Toncev G et al. The Prevalence of Pain in Adults with Multiple Sclerosis: A Multicenter Cross-Sectional Survey. Pain Med. 2015; 16(8): 1597-602.
27. Mesaroš Š, Drulović J. Dijagnoza muliple skleroze: uloga magnetne rezonance. U: Drulović J. Multipla skleroza. Medicinski fakultet Univerziteta u Beogradu 2013; 119-142.
28. Caucheteux N, Maarouf A, Genevray M, Leray E, Deschamps R, Chaunu MP et al. Criteria improving multiple sclerosis diagnosis at the first MRI. J Neurol. 2015; 262(4):979-87.
29. Hyun JW, Huh Sy, Kim W et al. Evaluation of 2016 MAGNIMS MRI criteria for dissemination in space in patients with a clinically isolated syndrome. Mult Scler. 2018; 24(6): 758-766.
30. Lourenco P, Shiran A, Saeedi J, Oger J, Schreiber A, Tremlett H. Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression. Mult Scler 2012;1(0):1-8.
31. Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N, Kappos L et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016; 15(3): 292-303.
32. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G et al. Diagnosis of multiple sclerosis: 2017 revision of the McDonald criteria. Lancet Neurol. 2018; 17(2):162-173.
33. Gaetani L, Prosperini L, Mancini A et al. 2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes. J Neurol. 2018;265(11):2684-2687.
34. Ruet A, Arrambide G, Brochet B, Auger C, Simon E, Rovira A, et al. Early predictors of multiple sclerosis after a typical clinically isolated syndrome. Mult Scler 2014; 20: 1721–26.
35. Castello MS, Alcala C, Mathur D, Rodas GL, Marti MB, Casanova B. Immunodetection of oligoclonal bands in serum and CSF of Multiple Sclerosis patients. Ann Neurosci. 2015; 22(1): 54.
36. Granď Maison F, Yeung M, Morrow SA, Lee L, Emond F, Ward BJ, et al. Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment. Curr Med Res Opin. 2018; 34(8):1419-1430.
37. Mero IL, Gustavsen MW, Saether HS, Flam ST, Hansen PB, Sondergaard HB et al. Oligoclonal band status in Scandinavian multiple sclerosis patients is associated with specific genetic risk alleles. PLos One. 2013;8(3):e58352 doi:10.1371/journal.pone.0058352
38. Imrell K, Landtblom AM, Hillert J, Masterman T. Multiple sclerosis with and without CSF bands: Clinically indistinguishable but immunogenetically distinct. Neurol. 2006;67(6): 1062-4.
39. Drulović J. Terapija koja modifikuje prirodni tok multiple skleroze. U: Drulović J. Multipla skleroza. Medicinski fakultet Univerziteta u Beogradu 2013; 161-182.
40. Drulovic J, Cukic M, Grgic S, Dincic E, Raicevic R, Congor N et al. The Impact of Betaplus Program on patient treatment satisfaction with interferon beta-1b in multiple sclerosis: Multicenter cross-sectional survey in the Western Balkan countries. Mult Scler Relat Disord. 2016; 11: 56-61.
41. Yadav SK, Mindur JE, Ito K, Dhib-Jalbut S. Advances in the immunopathogenesis of multiple sclerosis. Curr Opin Neurol. 2015;28:206–19.
42. Ontaneda D, Fox RJ. Progressive multiple sclerosis. Curr Opin Neurol. 2015;28:237–43.
43. Lanza CV, Bramanti P, Mazzon E et al. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis. Mult Scler Relat Disord. 2018;20:93-99.
44. Autor, 2014.
45. Engelborghs S et al. Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement (Amst). 2017; 8: 111–126.
46. Dominques RB et all. The cerebrospinal fluid in multiple sclerosis: far beyond the bands. Einstein. 2017.;15(1):100-104.
47. Brändle SM, Obermeier B, Senel M. et al. Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins.PNAS. 2016; 113(28) 7864-7869
48. Mc Nicholas N, Hutchinson M, McGuigan C, Chataway J. 2017 McDonald diagnostic criteria: A review of the evidence. Mult Scler Rel Disord. 2018; 24:48-54.
49. Arrambide G et al. The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. Brain. 2018; 141(4): 1-10.
50. Frau J, Villar LM, Sardu C, Secci MA, Schirru L, Ferraro D et al. Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor? J Neurol. 2018; 265(2):424-430.
51. Sun X, Bakhti M, Fitzner D et al. Quantified CSF antibody reactivity against myelin in multiple sclerosis. Ann Clin Transl Neurol. 2015; 2(12):1116–1123.
52. Katsavos S, Anagnostouli M. Biomarkers in Multiple Sclerosis: An Up-to-Date Overview. Mult Scler Int. 2013; 2013: 340-508.
53. Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi I, Topping J et al. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicenter study. MSJ 2015; 21(8):1 013–24.
54. Huang WJ, Chen WW, Zhang X. Multiple sclerosis: Pathology, diagnosis and treatments. Exp Ther Med. 2017; 13(6): 3163–3166.
2. Autor, 2013.
3. Drulović J. Analiza oligoklonalnog imunoglobulina G u diferencijalnoj dijagnozi neuroloških obolenja. Medicinski fakultet Univerziteta u Beogradu, doktorska disertacija, 1994.
4. Rolas JI, Patricco TS, Cristiana E. Oligoclonal bands in multiple sclerosis patients: worse prognosis. Neurol Res 2012;34(9):889-892.
5. Drulović J, Stojisavljević N, Dujmović. Findings of cerebrospinal fluid in the diagnosis of multiple scleorosis. Srp Arh Celok Lek 1995; 123: 7-8.
6. Dell Avvento S, Sotgio MA, Mance S, Sotgiu G, Sotgiu S. Epidemiology of multiple sclerosids in the pediatric population of Sardinia, Italy. Eur J Pediatr. 2016; 175(1): 19-21.
7. Waldman A, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu m, Banwell B. Multiple sclerosis in children: an update on clinical diagnosis therapeutic strategies, and research. Lancet Neurol. 2014; 13(9): 936-948.
8. Ghasemi N, Razavi S, Nikzad E. Multiple Sclerosis: Pathogenesis, Symptoms, Diagnosis and Cell-Based Therapy. Cell J 2017; 19(1): 1-10.
9. Holloman JP, Ho CC, Hukki A, Huntley JL, Gallicano GI. The development of hematopoietic and mesenchymal stem cell transplantation as an effective treatment for multiple sclerosis. Am J Stem Cells. 2013;2(2):95–107.
10. Gelfand JM. Multiple sclerosis: diagnosis, differential diagnosis, and clinical presentation. Handb Clin Neurol. 2014;122:269–290.
11. Fredrikson S. Clinical usefulness of cerebrospinal fluid evaluation. Intern Mult Scler J. 2010;17:24-27.
12. Dutta R, Trapp BD. Relapsing and progressive forms of multiple sclerosis – insights from pathology. Curr Opin Neurol. 2014; 27(3). 271-278.
13. Miller DH, Chard DT,Cicconelli O.Clinically isolated syndromes. Lancet Neurol 2012;11:157-169.
14. Dujmovic BI, Drulović J, Pekmezovic T. Prirodni tok i prognoza multiple skleroze. U: Drulović J. Multipla skleroza. Medicinski fakultet Univerziteta u Beogradu 2013; 32-46.
15. Lublin FD, Reingold CS, Cohen AJ, Cutter RG, Sorenson PS. Defining the clinical course of multiple sclerosis: he 2013. revisions. Neurology. 2014; 83(3): 278-286.
16. Stangel M, Fredrikson S, Meinl E, Petzold E. The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat Rev Neurol 2013;10:41.
17. Lublin FD. New multiple sclerosis phenotypic classification. Eur Neurol. 2014; 72(1):1-5.
18. Kale N. Optic neuritis as an early sign of multiple sclerosis. Eye Brain. 2016; 8: 195-202.
19. Adam MK, Krespan K, Moster ML, Serott RC. Simultaneous, Bilateral Ophthalmoplegia as the Presenting Sign of Paediatric Multiple Sclerosis: Case Report and Discussion of the Differential Diagnosis. Neuroophtalmology. 2014; 38(4): 230-237.
20. Avasarala JP, Cross AH, Trotter JL. Oligoclonal band number as a marker for prognosis in multiple sclerosis. Arch Neurol 2001;18:2044-2046.
21. Rolas JI, Patricco TS, Cristiana E. Oligoclonal bands in multiple sclerosis patients: worse prognosis. Neurol Res 2012;34(9):889-892.
22. Schneger R, Souza MD, Schindler C, Grize L, Dellas S, Radne EW. Prediction of long-term disability in multiple sclerosis. Mult Scler 2012;18(1):31-38.
23. Swanton JK, Rovira A, Tintore M, Altmann DR, Barkhof F, Filippi M et al. MRI criteria for multiple sclerosis in patient presenting with clinically isolated syndromes:a multicentre retrospective study. Lancet Neurol 2007;6:677-686.
24. Autor, 2011.
25. Aktas O, Wattjes MP, Sangel M, Hartung HP. Diagnosis of multiple sclerosis: revision of the McDonald criteria 2017. Nervenarzt. 2018 Jun 6. doi: 10.1007/s00115-018-0550-0.
26. Drulovic J, Basic-Kes V, Grgic S, Vojinovic S, Dincic E, Toncev G et al. The Prevalence of Pain in Adults with Multiple Sclerosis: A Multicenter Cross-Sectional Survey. Pain Med. 2015; 16(8): 1597-602.
27. Mesaroš Š, Drulović J. Dijagnoza muliple skleroze: uloga magnetne rezonance. U: Drulović J. Multipla skleroza. Medicinski fakultet Univerziteta u Beogradu 2013; 119-142.
28. Caucheteux N, Maarouf A, Genevray M, Leray E, Deschamps R, Chaunu MP et al. Criteria improving multiple sclerosis diagnosis at the first MRI. J Neurol. 2015; 262(4):979-87.
29. Hyun JW, Huh Sy, Kim W et al. Evaluation of 2016 MAGNIMS MRI criteria for dissemination in space in patients with a clinically isolated syndrome. Mult Scler. 2018; 24(6): 758-766.
30. Lourenco P, Shiran A, Saeedi J, Oger J, Schreiber A, Tremlett H. Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression. Mult Scler 2012;1(0):1-8.
31. Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N, Kappos L et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016; 15(3): 292-303.
32. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G et al. Diagnosis of multiple sclerosis: 2017 revision of the McDonald criteria. Lancet Neurol. 2018; 17(2):162-173.
33. Gaetani L, Prosperini L, Mancini A et al. 2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes. J Neurol. 2018;265(11):2684-2687.
34. Ruet A, Arrambide G, Brochet B, Auger C, Simon E, Rovira A, et al. Early predictors of multiple sclerosis after a typical clinically isolated syndrome. Mult Scler 2014; 20: 1721–26.
35. Castello MS, Alcala C, Mathur D, Rodas GL, Marti MB, Casanova B. Immunodetection of oligoclonal bands in serum and CSF of Multiple Sclerosis patients. Ann Neurosci. 2015; 22(1): 54.
36. Granď Maison F, Yeung M, Morrow SA, Lee L, Emond F, Ward BJ, et al. Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment. Curr Med Res Opin. 2018; 34(8):1419-1430.
37. Mero IL, Gustavsen MW, Saether HS, Flam ST, Hansen PB, Sondergaard HB et al. Oligoclonal band status in Scandinavian multiple sclerosis patients is associated with specific genetic risk alleles. PLos One. 2013;8(3):e58352 doi:10.1371/journal.pone.0058352
38. Imrell K, Landtblom AM, Hillert J, Masterman T. Multiple sclerosis with and without CSF bands: Clinically indistinguishable but immunogenetically distinct. Neurol. 2006;67(6): 1062-4.
39. Drulović J. Terapija koja modifikuje prirodni tok multiple skleroze. U: Drulović J. Multipla skleroza. Medicinski fakultet Univerziteta u Beogradu 2013; 161-182.
40. Drulovic J, Cukic M, Grgic S, Dincic E, Raicevic R, Congor N et al. The Impact of Betaplus Program on patient treatment satisfaction with interferon beta-1b in multiple sclerosis: Multicenter cross-sectional survey in the Western Balkan countries. Mult Scler Relat Disord. 2016; 11: 56-61.
41. Yadav SK, Mindur JE, Ito K, Dhib-Jalbut S. Advances in the immunopathogenesis of multiple sclerosis. Curr Opin Neurol. 2015;28:206–19.
42. Ontaneda D, Fox RJ. Progressive multiple sclerosis. Curr Opin Neurol. 2015;28:237–43.
43. Lanza CV, Bramanti P, Mazzon E et al. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis. Mult Scler Relat Disord. 2018;20:93-99.
44. Autor, 2014.
45. Engelborghs S et al. Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement (Amst). 2017; 8: 111–126.
46. Dominques RB et all. The cerebrospinal fluid in multiple sclerosis: far beyond the bands. Einstein. 2017.;15(1):100-104.
47. Brändle SM, Obermeier B, Senel M. et al. Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins.PNAS. 2016; 113(28) 7864-7869
48. Mc Nicholas N, Hutchinson M, McGuigan C, Chataway J. 2017 McDonald diagnostic criteria: A review of the evidence. Mult Scler Rel Disord. 2018; 24:48-54.
49. Arrambide G et al. The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. Brain. 2018; 141(4): 1-10.
50. Frau J, Villar LM, Sardu C, Secci MA, Schirru L, Ferraro D et al. Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor? J Neurol. 2018; 265(2):424-430.
51. Sun X, Bakhti M, Fitzner D et al. Quantified CSF antibody reactivity against myelin in multiple sclerosis. Ann Clin Transl Neurol. 2015; 2(12):1116–1123.
52. Katsavos S, Anagnostouli M. Biomarkers in Multiple Sclerosis: An Up-to-Date Overview. Mult Scler Int. 2013; 2013: 340-508.
53. Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi I, Topping J et al. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicenter study. MSJ 2015; 21(8):1 013–24.
54. Huang WJ, Chen WW, Zhang X. Multiple sclerosis: Pathology, diagnosis and treatments. Exp Ther Med. 2017; 13(6): 3163–3166.
Objavljeno
2020/09/30
Broj časopisa
Rubrika
Originalni naučni članak
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).